Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • ECB warns a house price correction is looming as interest rates rise
    • Military briefing: Ukraine’s battlefield agility pays off
    • China’s premier issues stark warning on economy as growth stalls
    • Military briefing: battle for Sievierodonetsk shows Russian strategy in Donbas
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Fed officials raised possibility of ‘restrictive’ policy to fight inflation
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • Elon Musk must find more cash for Twitter deal after scrapping margin loan
    • Pfizer warns of ‘constant waves’ of Covid as complacency grows
    • Andreessen Horowitz bets on crypto ‘golden era’ with new $4.5bn fund
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Elon Musk must find more cash for Twitter deal after scrapping margin loan
    • Pfizer warns of ‘constant waves’ of Covid as complacency grows
    • Klarna CEO says fintech will focus less on growth and more on ‘short-term profitability’
    • BofA and Citi suspend equity trading with Segantii Capital on block trade concerns
    • Vanguard refuses to end new fossil fuel investments
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news: Pentagon estimates Russia has lost nearly 1,000 tanks in Ukraine conflict
    • Live news updates from May 25: Musk must find cash for Twitter deal, Fed officials discussed ‘restrictive’ policy to fight inflation
    • Wall Street stocks make further gains after release of Fed minutes
    • Quant hedge funds reap windfall during 2022 market ructions
    • We’re asking the wrong questions about stablecoins
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Olivier Blanchard: ‘There’s a tendency for markets to focus on the present and extrapolate it forever’
    • Even Sue Gray’s scathing verdict is little threat to this prime minister
    • The supposed method in El Salvador’s crypto madness
    • Boris Johnson should heed warnings from the Australian election
    • No one is ready for the rising tide of climate litigation
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Race at work: how hard are companies really trying?
    • Vive la différence between work and play
    • Why presenteeism is an enduring corporate narcotic
    • ‘A bonfire of the decencies’: Peter Hennessy on Boris Johnson’s government
    • The cold call is back and worse than ever
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • The best of Cannes Film Festival 2022
    • Kylie Minogue, uncorked
    • The supposed method in El Salvador’s crypto madness
    • ‘It’s not flavourless. It’s delicate and really, really nice’: the UK’s lager revolution
    • Tom Cruise is back in the cockpit for humdinger spectacle Top Gun: Maverick
  • How to Spend It
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Illumina Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Sunday, 16 January, 2022
    Illumina says EU probe of $8bn Grail deal could hit biotech investment

    Chief executive deSouza attacks regulatory intervention over cancer test company

  • Wednesday, 18 August, 2021
    Illumina pushes ahead with closing $8bn Grail merger in defiance of EU probe

    US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline

  • Wednesday, 14 July, 2021
    Brooke Masters
    Competition enforcement is harder than it looks

    Novel antitrust cases complicate efforts to tackle climate change and healthcare

  • Tuesday, 1 June, 2021
    Illumina accuses US regulators of time-wasting over $8bn Grail deal

    Biotech group’s chief warns lives will be at risk if approval process is delayed

  • Thursday, 29 April, 2021
    Illumina sues Brussels over probe into $8bn cancer deal for Grail

    US genomics company takes rare step after authorities indicate they will review the deal

  • Wednesday, 31 March, 2021
    Lex
    Illumina: vertical acquisition in the crosshairs Premium content

    Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies

  • Tuesday, 23 February, 2021
    Genomics
    Genomic sequencing head calls for ‘Bio Force’ to detect virus threats

    Illumina’s Francis De Souza says global co-operation needed to keep up with new strains

  • Monday, 21 September, 2020
    Biotech
    Illumina agrees $8bn deal for cancer screening group Grail

    Genetic sequencing company set to take full ownership of start-up

  • Friday, 3 January, 2020
    Pharmaceuticals sector
    Illumina and Pacific Biosciences call off merger

    Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs

  • Monday, 30 July, 2018
    Technology sector
    Illumina shares lit up by earnings beat, outlook raise
  • Tuesday, 1 August, 2017
    Corporate earnings and results
    Illumina rises as its boosts forecast, posts earnings beat
  • Thursday, 10 November, 2016
    LexEuropean companies
    Siemens: healthy cynicism

    Separating the healthcare unit makes sense. Announcing it now does not

  • Tuesday, 11 October, 2016
    World
    Healthcare clocks sharpest decline in broad S&P 500 sell-off
  • Tuesday, 11 October, 2016
    US equities
    Illumina shares slide on sales ‘credibility gap’

    US stocks retreat as healthcare sector posts heaviest losses

  • Tuesday, 11 October, 2016
    US equities
    S&P falls 1% as US stocks extend declines
  • Monday, 10 October, 2016
    Companies
    Illumina tumbles 25% after sales warning
  • Thursday, 2 June, 2016
    Pharmaceuticals sector
    President raises patient and business hope for cancer treatment

    Many experts believe a new type of drug promises to revolutionise treatment

  • Friday, 1 April, 2016
    Pharmaceuticals sector
    Whole-genome breakthrough promises tonic for healthcare

    Accurately sequencing an individual’s DNA for less than $1,000 is now possible

  • Sunday, 13 March, 2016
    UK companies
    Cambridge Epigenetix secures $29m financing

    Google among backers for group aiming to commercialise epigenome

  • Wednesday, 16 December, 2015
    US downturn
    Fed rate rise: a reminder of the world in 2006
  • Tuesday, 6 October, 2015
    Oil
    DuPont boosted as chief bows out

    Chemical company under pressure from activist investor Nelson Peltz

  • Thursday, 5 June, 2014
    US equities
    Amazon gains in Nasdaq 100 advance
  • Tuesday, 8 January, 2013
    European banks
    Global pharma: check that pulse

    Patent cliff has been the industry’s excuse for a decade of underperformance

  • Thursday, 12 April, 2012
    European companies
    Roche persists with Illumina chase
  • Tuesday, 10 April, 2012
    Pharmaceuticals sector
    Roche and Illumina remain at loggerheads
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In